Using advanced MRI to identify high-risk areas in brain tumors for radiation planning
Using Advanced MR Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans: A Pilot Study, and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
This study is testing if advanced MRI can help doctors find the most dangerous parts of brain tumors to plan better radiation treatment for patients with malignant gliomas.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 135 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Memorial Sloan Kettering Cancer Center Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT00870129 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of advanced magnetic resonance imaging (MRI) techniques to identify high-risk areas within malignant gliomas, which are aggressive brain tumors. The goal is to determine if this imaging approach can enhance the planning of radiation therapy and assess changes in metabolites associated with gliomas and other solid tumors. Researchers aim to evaluate the safety and tolerability of these advanced imaging methods in patients with brain tumors. By improving the precision of radiation treatment, the study seeks to optimize patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a suspected or confirmed diagnosis of high-grade or low-grade glioma, particularly those with an isocitrate dehydrogenase (IDH) mutation.
Not a fit: Patients with extreme claustrophobia, known allergies to MRI contrast agents, or any contraindications to MRI or radiation therapy will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective radiation therapy plans for patients with malignant gliomas, potentially improving survival rates and quality of life.
How similar studies have performed: Other studies utilizing advanced MRI techniques for tumor characterization and treatment planning have shown promising results, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Suspected or Histopathologically proven diagnosis of high grade or low glioma or tumor is suspected to harbor an isocitrate dehydrogenase (IDH) mutation * May undergo radiation therapy * Patient and/or guardian is able to provide written informed consent prior to study registration * Age ≥ 18 years old Exclusion Criteria: * Extreme claustrophobia that precludes MRI scan * Known allergic reaction to Gd-DTPA * Any contraindication to gadolinium intravenous contrast as per standard Department of Radiology contrast guidelines * Any absolute contraindication to MRI (e.g., pacemaker, aneurysm clip, tissue expander). * Pregnant or nursing female * Unable to cooperate for MRI and/or radiation therapy planning
Where this trial is running
New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Robert Young, MD — Memorial Sloan Kettering Cancer Center
- Study coordinator: Robert Young, MD
- Phone: 212-639-8196
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.